- *Corresponding Author:
- Saudagar R.B
Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur-492 010, India.
E-mail: [email protected]
|Date of Received :||23 December 2005|
|Date of Revised :||24 June 2006|
|Date of Accepted :||18 February 2007|
|Indian J. Pharm. Sci., 2007, 69 (1): 149-152|
The present paper describes two simple, accurate, rapid, precise and economical procedures for simultaneous estimation of chlordiazepoxide and trifluoperazine hydrochloride in combined tablet dosage formulations. The first meth¬od is based on the multicomponent mode of analysis of the instrument used; the second method is developed on simultaneous equations. The Shimadzu 1700 pharmaspec UV/Vis spectrophotometer with a matched pair of 10 mm quartz cells was used for experimental purpose. Both the drugs obeyed Beer's law in the concentration range employed for the analysis. For all these methods 0.1 M HCl was used as a solvent. In this solvent system chlordiazepoxide showed maximum absorbance at a wavelength of 245 nm and trifluoperazine hydrochloride showed maximum absorbance at a wavelength of 255.5 nm. The results of analysis were validated statistically and by recovery studies.
The combinations containing chlordiazepoxide 10 mg and trifluoperazine hydrochloride 1 mg are available in tablet formulations. They are indicated in the treatment of anxiety and increase activity of the inhibitory transmitter GABA in different parts of CNS; they also produce antipsychotic, muscle relaxant and anticonvulsant activity. Chlordiazepoxide (CDZ), 7-chloro-2-(methyl amino)-5-phenyl-3H-1,4-benzodiazepine-4-oxide was the first benzodiazepine to be used clinically with general properties similar to those of diazepam  and used in the short-term treatment of anxiety disorders and insomnia.
The methods for quantitative estimation of chlordiazepoxide includes non-aqueous titrimetric , liquid chromatography [3-5], spectrophotometric methods [2,6-7] has been reported. Simultaneous determination of chlordiazepoxide from combined dosage forms with other drugs has been reported8-10. Trifluoperazine hydrochloride (TFP), 10-[3-(4-methyl-1-piperazinyl)propyl2- (trifluoromethyl) phenothiazine dihydrochloride is an antipsychotic and antiemetic. TFP is official in USP  and IP . Literature survey reveals that spectrophotometric [12-16] and HPLC [17-18] methods have been reported for its determination from pharmaceutical preparations. Several methods for simultaneous estimation have been reported in multi component drug formulations of TFP with other drugs [19-23]. No Spectrophotometric methods are reported in the literature for this combination. The proposed methods are rapid, simple, accurate, reproducible and economical for simultaneous estimation of CDZ and TFP from tablet dosage form.
Shimadzu 1700 pharmaspec UV/Vis spectrophotometer with a matched pair of 10 mm quartz cells was used in the present study. CDZ (analyzed sample) as provided by Aquila Labs Ltd and TFP (analyzed sample) as provided by Micro Laboratories Ltd. The chemicals used were of analytical grade. Freshly prepared 0.1 M hydrochloric acid (AR, S. D. Fine Chemicals, Mumbai) in double distilled glass water was used in present investigation. The commercially available marketed tablet brands Serepose (Unimarck Pharma, Chandigarh) and Trisar (Sara health care, Vadodara) containing 10 mg of CDZ and 1 mg of TFP has been used for estimation.
Standard stock solutions of CDZ and TFP were prepared separately by dissolving 100 mg of each drug in 0.1 M hydrochloric acid solution. Each stock solution was suitably diluted to different concentrations and linearity was studied. Linear relationships were observed in the range 2-50 μg/ml for CDZ and 2-35 μg/ml for TFP. These stock solutions were further diluted to get concentration of 10 μg/ml of each drug using 0.1 M hydrochloric acid solution.
Twenty tablets were weighed and average weight was calculated. For methods 1 and 2, powder equivalent to 10 mg of CDZ and 1 mg of TFP was accurately weighed. The mixture was extracted with 0.1 M HCl, the extract was filtered, and the filtrate was approximately diluted to get final concentration 30 μg /ml of CDZ and 3 μg/ml of TFP. The analysis procedure was repeated five times with tablet formulations available in market.
In method 1 multicomponent analysis  was applied, since the spectra of drugs overlapped. Sample solutions of CDZ and TFP of the concentration of 10 μg/ml were prepared in 0.1 M HCl and their solutions were found to be stable for more than 12 h. These solutions were scanned over the range of 400 nm to 200 nm in the multicomponent mode using 245.0 nm and 255.5 nm as sampling wavelengths. The overlain zero order spectra of CDZ and TFP are shown in fig.1. The figure indicates that absorption maximum of CDZ is at wavelength 245.0 nm, while TFP has absorption maximum at 255.5 nm. Then mixed standard solution of same concentration was prepared and scanned over the same range. An overlain spectrum of the mixed standards was used to determine the concentration of two drugs in the tablet sample solutions. The sample solution containing 10 μg/ml of CDZ and 10 μg/ml of TFP was scanned over the range of 400 nm to 200 nm in the multicomponent mode and the concentration of each component were obtained by the spectral data of the sample solutions with reference to that of the mixed standards. From the concentration the amount was calculated by using the formula, amount = concentration×dilution factor×average weight/weight taken.
In method 2, simultaneous equations (Vierordt’s method)  was applied for determination of both the drugs. Selection of analytical wavelengths was done by taking pure drug samples of CDZ and TFP, which were separately dissolved in 0.1 M HCl to give two solutions of 10 μg /ml. They were scanned in the wavelength range of 400 to 200 nm. Wavelengths 245 and 255.5 nm was selected for the formation of the simultaneous equations. For constructing calibration curves, two series of different concentrations of CDZ and TFP were prepared from the stock solutions.
The first series contained 1-15 μg/ml and the second series contained 2-30 μg/ml of CDZ and TFP respectively. Their absorbance was measured and calibration curves were plotted at 245.0 and 255.5 nm, respectively. The absorptivities (A 1%, 1 cm) of both the drugs at both the wavelengths were determined. These calculated values were the mean of five independent determinations. The concentration of each of CDZ and TFP were determined by using the following equations, A= 1273.7CCDZ+393.5CTFP (at λ245.0), and A2= 1130.3CCDZ+630.5CTFP(at λ255.5), where A1, A2 are absorbance of the mixture at 245.0 nm and 255.5 nm, respectively, 1273.7 and 1130.3 are absorptivities of CDZ at 245 nm and 255.5 nm, respectively, 393.5 and 630.5 absorptivities of TFP at 245 nm and 255.5 nm, respectively, CCDZ is the concentration of the CDZ and CTFP is the concentration of the TFP. The absorbance A and A of the tablet 12 solutions were recorded at 245 nm and 255.5 nm, respectively, and the concentration of two drugs in the sample were determined by substituting A1 and A2 values of sample solution in equation. Recovery studies were performed by the addition of known amount of standard drug solution of CDZ and TFP to pre-analyzed tablet solution and the resulting solutions were analyzed by proposed methods.
The proposed multicomponent mode of analysis method is specific for this instrument. It employs a programme for the simultaneous quantification of up to eight components and their mixtures. The main advantage of this method is that there is no need for calibration or manual calculations. The reporting is done by the microprocessor of the instrument. All the methods were found to be economical, as they require only 0.1 M HCl as solvent. The validation and sensitivity parameters of both the method is presented in Table 1. The values of standard deviation, coefficient of variation, standard error were satisfactorily low and recovery lying between 99 to 102% (for CDZ) and 99 to 101% (for TFP), which indicates the accuracy of the methods. The methods employing simultaneous equations are very simple and can be easily applied to routine analysis. The results of analysis of tablet formulations, statistical evaluation and recovery studies are shown in Tables 2 and 3, respectively. The overlain spectrum of CDZ and TFP used for analysis is given in fig. 1.
|Parameters||Method I||Method II|
|Wavelength for measurement (nm)||245||255.5||245||255.5|
|Beer’s Law range (µg /ml)||2-50||2-35||2-50||2-35|
|Sandell’s sensitivity (µg /ml/cm2 /0.001 abs. unit )||0.008067||0.015860||0.007851||0.015840|
|Molar extinction coefficient (0.001abs. unit/mole. cm/dm3) Regression values:||3.716261×104||3.027564×104||3.81850×104||3.032368×104|
|i. Slope (Yp)||0.1229||0.0633||0.1345||0.0684|
|ii. Intercept on y-axis||0.0218||-0.0056||0.0242||-0.0062|
|Correlation coefficient (r2)q||0.9995||0.9999||0.9997||0.9999|
pmeans Y=mx+C, where ?C? is concentration in ?g/ml and Y is absorbance unit, qmeans five replicate samples, CDZ is chlordiazepoxide and TFP is trifluoperazine hydrochloride; method I is multicomponent mode of analysis and method II is simultaneous equation method.
Table 1: Validation and Sensitivity of the Proposed Method.
|Label claim||%Amount found*|
|(mg / tab.)||TFP||CDZ|
|TFP||CDZ||Method I||Method II||Method I||Method II|
*Each reading is an average of six replicates. CDZ is chlordiazepoxide and TFP is trifluoperazine hydrochloride; SD refers to standard deviation, method I is multicomponent mode of analysis and method II is simultaneous equation method.
Table 2: Results of analysis of commercial .
|TFP tablet||TFP added||% Recovery*||CDZ tablet||CDZ added||% Recovery*|
|(μg/ml)||(μg /ml)||Method I||Method II||(μg/ml)||(μg/ml)||Method I||Method II|
% of recovery =100×(recovered amount/added amount), *Each reading is an average of three replicates. CDZ is chlordiazepoxide and TFP is trifluoperazine hydrochloride; SD refers to standard deviation, method I is multicomponent mode of analysis and method II is simultaneous equation method.
Table 3: Results of recovery studies.
The proposed methods are accurate, precise, economical, rapid, and selective for the simultaneous determination of trifluoperazine hydrochloride and chlordiazepoxide in tablet dosage form. Hence it can be conveniently adopted for the routine quality control analysis in its combined dosage forms.
We are grateful to Micro Laboratories Ltd., Hosur (T.N.) 18. Abdel-Moety, E.M. and Al-deeb, O.A., Eur. J. Pharm. Sci., 1997, and Aquila Labs Ltd. Kanjari (Guj.) for providing gift samples of trifluoperazine hydrochloride and 389. chlordiazepoxide to carry out this research work. The authors are also grateful to Director, Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (C.G.) for providing facility to carry out research work Authors wish to thank AICTE, New Delhi for financial assistance under the scheme of RPS.
- Parfitt, K., Eds., In; Martindale, The complete Drug Reference, 33rd Medknow Edn., The Pharmaceutical Press, London, 2002, 659.
- Indian Pharmacopoeia, Vol. I, 4th Edn., Government of India,by Ministry of Health and Family Welfare, New Delhi, 1996, 166.
- United States Pharmacopoeia/NF, 26th /21st Edn., The U.S.is Pharmacopoeial convention, Inc., Rockville, MD., 2003, 414.
- Jalal, J.M., Hussen, A. and Khalil, H.S., Anal. Lett., 1987, 20, 635.
- Selavaka, C.M., Krull. and Zune, I.S., J. Chromatogr. Sci., 1985, 23, 499.
- Walash, M.I. and El-Brashy, A., Talanta, 1988, 359, 895.
- Manes, J., Civera, J., Front. G. and Bosch, F., Clin. Ind. Farm., 1987, 6, 333.
- Shinde, V.M., Tendolkar, N.M. and Desai, B.S., Indian J. Pharm. Sci., 1995, 57, 66.
- Shirke, P.P. and Patel, M.K., Eastern Pharmacist, 1994, 37, 179.
- Toral M.I., Raichter P. and Lara N., Int. J. Pharm., 1999, 189, 67.
- UnitedStatesPharmacopoeia/NF, 26th /21st Edn., The U.S.Pharmacopoeiaconvention, Inc., Rockville, MD., 2003, 1880.
- IndianPharmacopoeia, Vol. II, 4th Edn., Government of India,Ministry of Health and FamilyWelfare, New Delhi, 1996, 775.
- Waston, J.R., J. Pharm. Sci., 1970, 59, 391
- Radhkrishnamurty, C. and Rao, G.S., J. Inst. Chem. India., 1984, 56, 79.
- Zarapkar, S.S. and Athlye, K.R., IndianDrugs, 1988, 26, 32.
- Kamalapur, O.S. and Sanjay, R.S., Eastern Pharmacist, 1982, 25, 179.
- Patela, Y.P., Dhorda, U.J. and Sundaresan, M., Talanta, 1998, 47, 625.
- Abdel-Moety, E.M. and Al-deeb, O.A., Eur. J. Pharm. Sci., 1997, 5, 1.
- Desai, S.M., Khatri, J.M. and Lalla, J.K., IndianDrugs, 1990, 27, 389.
- El-Gindy, A., El-Zeany, B.T. and Shabana, M.M., J. Pharm. Biomed. Anal., 2001, 26, 203.
- El-Gindy, A., El-Zeany, B.T and Shabana, M.M., J. Pharm. Biomed. Anal., 2002, 32, 9.
- Mahadik, K.R., Aggarwal,.H. and Kaul, N., IndianDrugs, 2003, 40, 340.
- Trivedi, P. and Sachan, A., Eastern Pharmacist, 1999, 42, 117.
- Moffat, A.C., editors. Clarke?sIsolation and Identification of Drugs. 2nd Edn.,.ThePharmaceuticalPress, London, 1986, 228.
- Beckett, A.H. and Stenlake, J.B., In; PracticalPharmaceuticalChemistry. 4th Edn., Vol. II, CBC Publishers and Distributors, New Delhi,1998, 284.